Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Teva wins US court ruling on generic breast cancer drug

Bristol-Myers Squibb’s Baraclude has $314 million in US annual sales.

Baraclude TEVA

 

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. Court of Appeals for the Federal Circuit today upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb’s entecavir compound claim of U.S. Patent No. 5, 206, 244 invalid. Teva’s ANDA for entecavir has received tentative approval from the U.S. Food and Drug Administration (FDA).

Teva will finalize the launch plans for this product once it receives final approval from the FDA.

Baraclude is marketed in the U.S. by Bristol-Myers Squibb and had annual sales of approximately $314 million in the United States, according to IMS data as of March 2014.

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement